According to a new subgroup analysis of the COMPASS trial published in the Journal of the American College of Cardiology, the prevention of Major Adverse Limb Events (MALE) is of utmost importance in patients with lower extremity Peripheral Arterial Disease (PAD) due to its poor prognosis. Additionally, it has been found that the aspirin and rivaroxaban 2.5mg twice daily combination leads to a significant reduction of Major Adverse Limb Events (MALE) in these patients.
Dr. Sonia Anand Speaks at Brigham and Women’s Hospital
EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study), a randomized clinical trial, published in the Journal of the American Medical Association, provides evidence that smoking cessation medications do not increase the risk of serious cardiovascular events in the general population of smokers. Continue reading
Dr. John Eikelboom Speaks at Brigham and Women’s Hospital
Dr. C. Michael Gibson discusses the trial findings with Dr. Mary McDermott at AHA 2017.
Dr. Kenneth Rosenfield and Dr. C. Michael Gibson Discuss